The short version
8 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Transderm Scop
Scopolamine · SCOPOLAMINE 1 mg/3d · Patch, Extended Release · Transdermal · Baxter Healthcare Corporation
NDC 10019-0008-01 · 1 PATCH in 1 POUCH / 3 d in 1 PATCH · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$11.60per dosage unitgross, before rebates — matched by drug name · 2024
- Medicaid generic ceiling (FUL)$4.33per TDPweighted avg manufacturer price $2.0226 · Aug 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for scopolamine (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- NDA017874
- TE code
- AB
- Approval date
- Jan 1, 1982
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedApr 13, 2022Mckesson Medical-Surgical Inc. Corporate Office — cGMP deviations: Temperature abuse
Manufacturers of Scopolamine (Patch, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bryant Ranch Prepack | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 3, 2026 |
| Amneal Pharmaceuticals NY LLC | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 2, 2026 |
| Ingenus Pharmaceuticals, LLC | SCOPOLAMINE 1.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals, Inc. | SCOPOLAMINE 1.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rhodes Pharmaceuticals LLC | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | SCOPOLAMINE 1 mg/3d | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Transderm Scop — NDC 10019-0008-01," retrieved September 3, 2026, https://drugdashboards.com/drug/10019000801.
Free to cite with attribution — see how the data is put together.